Sebastian E. Serfling

1.4k total citations
65 papers, 902 citations indexed

About

Sebastian E. Serfling is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sebastian E. Serfling has authored 65 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 24 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sebastian E. Serfling's work include Radiopharmaceutical Chemistry and Applications (19 papers), Neuroendocrine Tumor Research Advances (16 papers) and Prostate Cancer Treatment and Research (15 papers). Sebastian E. Serfling is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (19 papers), Neuroendocrine Tumor Research Advances (16 papers) and Prostate Cancer Treatment and Research (15 papers). Sebastian E. Serfling collaborates with scholars based in Germany, United States and Japan. Sebastian E. Serfling's co-authors include Andreas K. Buck, Rudolf A. Werner, Thomas Lindner, Andreas Schirbel, Takahiro Higuchi, Philipp E. Hartrampf, Constantin Lapa, Clemens Kratochwil, Frederik L. Giesel and Alexander Weich and has published in prestigious journals such as European Urology, Journal of Nuclear Medicine and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Sebastian E. Serfling

63 papers receiving 897 citations

Peers

Countries citing papers authored by Sebastian E. Serfling

Since Specialization

Citations

This map shows the geographic impact of Sebastian E. Serfling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sebastian E. Serfling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sebastian E. Serfling more than expected).

Fields of papers citing papers by Sebastian E. Serfling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sebastian E. Serfling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sebastian E. Serfling. The network helps show where Sebastian E. Serfling may publish in the future.

Co-authorship network of co-authors of Sebastian E. Serfling

This figure shows the co-authorship network connecting the top 25 collaborators of Sebastian E. Serfling. A scholar is included among the top collaborators of Sebastian E. Serfling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sebastian E. Serfling. Sebastian E. Serfling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma 2025 ·Clinical Nuclear Medicine ·(unknown), Sebastian E. Serfling, (unknown), Philipp E. Hartrampf, Takahiro Higuchi, Matthias Scheich, Stephan Hackenberg, Andreas K. Buck, Joachim P. Steinbach, Rudolf A. Werner, (unknown), Marinela Augustin	1
2	SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors 2025 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Miriam Müller, Heribert Hänscheid, Sebastian E. Serfling, Kerstin Michalski, (unknown), Bülent Polat, Andreas K. Buck, Rudolf A. Werner, Philipp E. Hartrampf	2
3	Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma 2025 ·Clinical Nuclear Medicine ·(unknown), (unknown), Sabrina Kraus, Leo Rasche, Takahiro Higuchi, Samuel Samnick, Constantin Lapa, Hermann Einsele, Sebastian E. Serfling, Andreas K. Buck, Rudolf A. Werner	0
4	Monitoring Dual-Cancer Treatment in a Patient With Prostate and Hepatocellular Carcinoma Using Prostate-Specific Membrane Antigen-Directed PET/CT 2024 ·Clinical Nuclear Medicine ·Florian P. Reiter, Alexander Weich, Takahiro Higuchi, Sebastian E. Serfling, Ralph Kickuth, Rudolf A. Werner	2
5	Evaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological Studies 2024 ·Molecular Imaging and Biology ·(unknown), Rudolf A. Werner, Sebastian E. Serfling, Andreas K. Buck, Aleksander Kosmala, Takanori Sasaki, Alexander Weich, Takahiro Higuchi	1
6	Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas 2024 ·Molecular Imaging and Biology ·Kerstin Michalski, (unknown), Philipp E. Hartrampf, (unknown), Sebastian E. Serfling, Andreas K. Buck, Rudolf A. Werner, Aleksander Kosmala, Alexander Weich	1
7	FAPI-PET in Cardiovascular Disease 2024 ·Seminars in Nuclear Medicine ·Takahiro Higuchi, Sebastian E. Serfling, David M. Leistner, Thimoteus Speer, Rudolf A. Werner	7
8	SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·Philipp E. Hartrampf, (unknown), Anna Katharina Seitz, Hubert Kübler, Sebastian E. Serfling, (unknown), Kerstin Michalski, Steven P. Rowe, Martin G. Pomper, Andreas K. Buck, Uta Eberlein, Rudolf A. Werner	21
9	Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures 2023 ·Cancers ·(unknown), Philipp E. Hartrampf, Philip Kollmannsberger, Antonio Giovanni Solimando, Svenja Meierjohann, Hubert Kübler, Ralf C. Bargou, Bastian Schilling, Sebastian E. Serfling, Andreas K. Buck, Rudolf A. Werner, Constantin Lapa, Markus Krebs	4
10	Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors 2023 ·Clinical Nuclear Medicine ·Alexander Weich, Sebastian E. Serfling, (unknown), Takahiro Higuchi, Philipp E. Hartrampf, Andreas Schirbel, (unknown), Andreas K. Buck, Steven P. Rowe, Aleksander Kosmala, Rudolf A. Werner	7
11	[18F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patients 2023 ·Endocrine ·(unknown), Takahiro Higuchi, Stephan Hackenberg, Rudolf Hagen, (unknown), Agmal Scherzad, Andreas K. Buck, Rudolf A. Werner, Sebastian E. Serfling	1
12	In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target 2023 ·Cancers ·(unknown), (unknown), (unknown), Andreas Schindele, Malte Kircher, Alexander Dierks, Christian H. Pfob, Sebastian E. Serfling, Andreas K. Buck, Theo Pelzer, Takahiro Higuchi, Alexander Weich, Ralph A. Bundschuh, Rudolf A. Werner, Constantin Lapa	4
13	Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy 2023 ·Annals of Nuclear Medicine ·Kerstin Michalski, Aleksander Kosmala, Rudolf A. Werner, Sebastian E. Serfling, Anna Katharina Seitz, Constantin Lapa, Andreas K. Buck, Philipp E. Hartrampf	5
14	Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·Aleksander Kosmala, Sebastian E. Serfling, Kerstin Michalski, Thomas Lindner, Andreas Schirbel, Takahiro Higuchi, Philipp E. Hartrampf, Thorsten Derlin, Andreas K. Buck, Alexander Weich, Rudolf A. Werner	8
15	Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up 2022 ·European Journal of Nuclear Medicine and Molecular Imaging ·Philipp E. Hartrampf, Anna Katharina Seitz, (unknown), Sebastian E. Serfling, Andreas Schirbel, Steven P. Rowe, Hubert Kübler, Andreas K. Buck, Rudolf A. Werner	21
16	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸Ga-PentixaFor PET 2022 ·Journal of Nuclear Medicine ·Andreas K. Buck, Alexander Haug, (unknown), Alessandro Lambertini, Takahiro Higuchi, Constantin Lapa, Alexander Weich, Martin G. Pomper, Hans‐Jürgen Wester, (unknown), Andreas Schirbel, Samuel Samnick, Marcus Hacker, Verena Pichler, Stefanie Hahner, Martin Faßnacht, Hermann Einsele, Sebastian E. Serfling, Rudolf A. Werner	55
17	Therapeutic Effects of Lipid Lowering Medications on Myocardial Blood Flow, Inflammation, and Sympathetic Nerve Activity Using Nuclear Techniques 2022 ·Current Cardiology Reports ·Takahiro Higuchi, Sebastian E. Serfling, Steven P. Rowe, Rudolf A. Werner	1
18	Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Christian Linz, Roman C. Brands, Olivia Kertels, Alexander Dierks, Joachim Brumberg, Elena Hartmann, Stefan Hartmann, Andreas Schirbel, Sebastian E. Serfling, (unknown), Andreas K. Buck, Alexander Kübler, (unknown), Constantin Lapa, Malte Kircher	37
19	Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Philipp E. Hartrampf, Bernhard Petritsch, Andreas K. Buck, Sebastian E. Serfling	7
20	DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA 2019 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Harry Scherthan, Constantin Lapa, Sebastian E. Serfling, (unknown), Michael Laßmann, Uta Eberlein	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact